

1 **Choriocapillaris flow impairment predicts the development and**  
2 **enlargement of drusen**

3 **Marco Nassisi<sup>1,2</sup>, Tudor Tepelus<sup>1,2</sup>, Muneeswar Gupta Nittala<sup>1,2</sup>, Srinivas R. Sadda<sup>1,2,3</sup>.**

4

5 1. Doheny Image Reading Center, Doheny Eye Institute, 1350 San Pablo St., DVRC211, Los Angeles,  
6 CA, 90033, USA.

7 2. Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

8 3. Corresponding author: ssadda@doheny.org

9

10

11

12

13

14

15

16

17

18

19 Number of words: 2451

20

21

22

23

24 **Abstract**

25 **Purpose:** To evaluate the choriocapillaris flow in regions of enlarged or new incident drusen in patients  
26 with early and intermediate age-related macular degeneration (AMD).

27 **Methods:** We retrospectively reviewed and analyzed structural optical coherence tomography (OCT)  
28 and OCT angiography (OCTA) images of consecutive patients with early or intermediate AMD evaluated  
29 at the Doheny-UCLA Eye Centers between 2015 and 2018. All patients were imaged using a Cirrus OCT,  
30 and only one eye was included in the study. To be eligible for this analysis, patients were required to  
31 have a 3 x 3 mm OCTA scan acquired during the first visit (considered as baseline) and a fovea-centered  
32 512 x 128 macular cube (6 x 6 mm) acquired at both the baseline visit and after a minimum of 1 year  
33 follow-up. The drusen maps generated from the macular cubes were used to generate a drusen area  
34 (DA) measurement and compute the difference between baseline and follow-up ( $\Delta DA$ ). After registering  
35 the structural OCTs to the baseline choriocapillaris (CC) OCTA, we analyzed and compared the baseline  
36 flow deficits (FD) within drusen free region ( $FD_{DF}$ ), regions into which drusen enlarged or expanded at  
37 follow-up ( $FD_{EN}$ ), and regions in which new incident drusen ( $FD_{ND}$ ) appeared at follow-up.

38 **Results:** Forty-six patients were eligible for the analysis and had a mean follow-up of 1.47 years. Twelve  
39 eyes of 12 subjects had a  $\Delta DA < 0.1 \text{ mm}^2$ . In these eyes only the  $FD_{DF}$  was calculated ( $40.37 \pm 2.29\%$ ) and it  
40 was not significantly different from the  $FD_{DF}$  of eyes with  $\Delta DA \geq 0.1 \text{ mm}^2$  ( $40.25 \pm 4.37\%$ ,  $p=0.849$ ). When  
41 comparing the different regions within the eyes with  $\Delta DA \geq 0.1 \text{ mm}^2$ , there was no significant difference  
42 between  $FD_{ED}$  and  $FD_{ND}$  ( $43.61 \pm 4.36\%$  and  $44.16 \pm 2.38\%$ ,  $p=0.528$ ), but both were significantly higher than  
43  $FD_{DF}$  ( $p=0.001$  and  $p<0.001$  respectively).

44 **Conclusions:** Significant CC flow impairment is present under regions of intact RPE where existing  
45 drusen will enlarge into or new drusen will appear within 2 years. These findings suggest that location of  
46 drusen may not be stochastic, but may be driven by regional deficits in the choriocapillaris.

47 Keywords: age-related macular degeneration, optical coherence tomography angiography, drusen,  
48 choriocapillaris.

49

## 50 **Introduction**

51 Age related macular degeneration (AMD) can result in progressive and irreversible central vision loss  
52 among older individuals[1]. Drusen is a characteristic feature of the early and intermediate stages of the  
53 disease. AMD is a complex disease with multifactorial etiologies with aging, genetics, inflammation,  
54 oxidative damage, and environmental influences all having been implicated in its pathogenesis and  
55 progression. [2, 3] Regardless of the etiologic mechanism, the AMD disease process ultimately results in  
56 damage to the retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris (CC) unit.[4, 5]  
57 The dysfunction of this complex may contribute to the development of drusen between the RPE and  
58 Bruch's membrane with eventual progressive RPE and CC loss and photoreceptor atrophy.

59 Multiple studies on histopathologic samples have suggested that CC loss may be an important early  
60 finding in the evolution of AMD, but whether it is a primary dysfunction or it is secondary to RPE  
61 abnormalities, remains a topic of controversy. Histologic studies, of course, are not amenable to  
62 longitudinal follow-up, and thus the sequence of events has been difficult to establish. Recently, optical  
63 coherence tomography angiography (OCTA) has evolved into a useful non-invasive imaging technology  
64 that allows the retinal and choriocapillaris circulations to be evaluated and quantified *in vivo*. With OCTA  
65 imaging, the CC has a grainy appearance with bright spots corresponding to flow alternating with dark  
66 regions which have been referred to as flow voids. The appearance of the CC may change with age,  
67 myopia, or retinal diseases[6, 7]. Flow voids evident on OCTA images of the CC may represent normal  
68 intercapillary spaces, but they may also be secondary to CC dropout.[8] However, it is important to note  
69 that the detectable flow range of OCTA is limited, and flows below the decorrelation threshold are

70 indistinguishable from background noise and are thus undetectable[8]. Considering this, CC flow voids  
71 have recently been renamed flow or signal deficits[9]. Thanks to advanced image processing software,  
72 the quantification of these CC flow deficits is now possible, allowing an estimation of CC flow  
73 impairment in different diseases[8, 10–13]. The main aim of this study was to correlate the CC  
74 impairment with the incidence of new drusen in patients with early or intermediate AMD, using OCTA  
75 analysis.

## 76 **Methods**

77

78 In this retrospective study, we collected and analyzed structural OCT and OCTA images of consecutive  
79 patients with early and intermediate AMD acquired at the Doheny Eye Centers between 2015 and 2018  
80 using the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) with Angioplex OCTA software.

81 Eligible patients had drusen on OCT in at least one eye and no evidence of any other pathology involving  
82 the macula. Eyes with non-visually significant vitreoretinal interface disease, such as a subtle epiretinal  
83 membrane only visible by OCT, were not excluded. All eligible patients needed to have one 3 x 3 mm  
84 OCTA scan acquired during the first visit (considered as baseline) and two fovea-centered 512 x 128  
85 cubes (6 x 6 mm) acquired at baseline and at a second visit with a follow-up of at least 12 months. Only  
86 subjects with scans that fulfilled the image quality acceptance criteria (signal strength >7, absence of  
87 motion artifact) of the Doheny Image Reading Center (DIRC) according to the evaluation of two certified  
88 readers, were selected and analyzed[14, 15]. When both eyes were eligible, the right eye was chosen for  
89 the analysis.

90

## 91 **Image Analysis**

92

93 The two fovea-centered 512 x 128 macular cubes (6 x 6 mm) for each eligible eye were used to generate  
94 the respective drusen maps by the FDA-cleared Cirrus RPE analysis software (Cirrus HD-OCT, software  
95 V.6.0; Carl Zeiss Meditec, Inc., Dublin, CA, USA). The drusen map is a color-encoded elevation map  
96 generated using a slab between the RPE and the RPE fit line. The accuracy and reproducibility of the  
97 drusen map, has been demonstrated in previous studies[16]. The map was verified using the  
98 corresponding structural B-scans and if any errors were present due to segmentation, the latter was  
99 manually refined by the operator.

100 The 3 x 3 mm OCTA scan consisted of a 245 A-scans x 245 B-scan pattern. A fully-automated retinal layer  
101 segmentation algorithm was applied to the three-dimensional structural OCT data, in order to segment  
102 the CC slab as defined previously (10  $\mu$ m thick starting 31  $\mu$ m posterior to the RPE reference).[6] This  
103 segmentation was then applied to OCTA flow intensity data to obtain vascular images. Maximum  
104 projection analyses of the flow intensity were performed to generate the *en-face* images of the CC  
105 (1024x1024 pixels). Projection artifacts were removed using the automated algorithm included with the  
106 instrument software.

107 Both drusen maps and the CC *en face* image were registered using ImageJ software version 1.50  
108 (National Institutes of Health, Bethesda, MD; available at <http://rsb.info.nih.gov/ij/index.html>)[17]. The  
109 large superficial vessels visible on OCTA and on the OCT fundus image of the 6 x 6 mm scans (i.e. the *en*  
110 *face* reconstruction of the sum of all the signals coming from each of the A-scans acquired [18]) were  
111 used as a reference for the registration.

112 The registered drusen maps were thresholded using the “Max Entropy” method after splitting the color  
113 channels and selecting the green channel image. The resulting binarized images were analyzed using  
114 the “Analyze particles” command in order to obtain the drusen areas (DA) and compare them between  
115 the baseline and follow-up visits. Based on the difference between the two values, patients were divided

116 into 2 groups: subjects with stable DA (difference between DA at baseline and follow-up [ $\Delta DA$ ]  $<0.1$   
117  $\text{mm}^2$ ); subjects with increased DA after follow-up ( $\Delta DA >0.1 \text{ mm}^2$ ).

118 The CC *en-face* image was binarized for quantitative analysis of the signal deficits using the Phansalkar  
119 method (radius, 15 pixels) as previously described.[6, 19, 20]

120 Using the selection from both drusen maps, the flow deficits could be calculated in three different  
121 zones: drusen free region ( $FD_{DF}$ ), region of enlarged drusen ( $FD_{ED}$ ), region of new drusen ( $FD_{ND}$ ) (Fig. 1).

122 For patients with  $\Delta DA <0.1 \text{ mm}^2$ , only the  $FD_{DF}$  was calculated. For patients with  $\Delta DA >0.1 \text{ mm}^2$ ,  $FD_{DF}$   
123 and  $FD_{ED}$  were always calculated, while  $FD_{ND}$  was calculated only in presence of new drusen in the  
124 follow-up visit.

125 The entire procedure was repeated by two independent, experienced operators in order to investigate  
126 the repeatability of all measurements. All values were then averaged to perform the statistical analysis.

127

## 128 **Statistics**

129 Statistical analyses were performed using SPSS Statistics version 20 (IBM, Armonk, NY). Intraclass  
130 correlation coefficients (ICC) were calculated for drusen area and CC flow deficit measurements.

131 The differences between the two cohorts and among the different regions were investigated with the  
132 Mann-Whitney test. All data are presented as mean  $\pm$  standard deviation, median and interquartile  
133 range (IQR: third quartile – first quartile). In all analyses, P values  $< 0.05$  were considered as statistically  
134 significant.

135

## 136 **Results**

137  
138 Forty-eight patients (23 males, mean age:  $79.5 \pm 7.26$  years, median: 79.5, IQR: 84.25 - 75) met the  
139 eligibility criteria for this retrospective analysis (Fig 2). The mean follow-up time was  $1.47 \pm 0.32$  years  
140 (median: 1.43, IQR: 1.67 – 1.24) .

141 Among those subjects only 12 had a  $\Delta DA < 0.1 \text{ mm}^2$ . All remaining subjects had an increase of  $DA \geq 0.1$   
142  $\text{mm}^2$  and 25 of them had new incident drusen in the second visit.

143 The mean DA at baseline ( $DA_B$ ) was  $0.87 \pm 0.59 \text{ mm}^2$  (median 0.72, IQR: 1.15 – 0.5) and at follow-up  
144 ( $DA_F$ ) it was  $1.15 \pm 0.71 \text{ mm}^2$  (median: 0.9, IQR: 1.56 – 0.65). More specifically, patients with  $\Delta DA < 0.1$   
145  $\text{mm}^2$  had a mean  $DA_B$  of  $0.64 \pm 0.33 \text{ mm}^2$  (median: 0.55, IQR: 0.78 – 0.46) and a mean  $DA_F$  of  $0.69 \pm 0.33$   
146  $\text{mm}^2$  (median: 0.6, IQR: 0.82 – 0.5) while patients with  $\Delta DA \geq 0.1 \text{ mm}^2$  had a mean  $DA_B$  of  $0.95 \pm 0.64 \text{ mm}^2$   
147 (median: 0.73, IQR: 1.23 – 0.54) and a mean  $DA_F$  of  $1.31 \pm 0.73 \text{ mm}^2$  (median: 0.97, IQR: 1.76 – 0.79).

148 The 12 subjects with no significant increase in DA, had a  $FD_{DF}$  of  $40.37 \pm 2.29 \%$  (median: 41.23, IQR:  
149 42.21 – 38.31) while the other 36 had a  $FD_{DF}$  of  $40.25 \pm 4.37 \%$  (median: 40.36, IQR: 42.75 – 37.9)  
150 ( $p=0.849$ ).

151 When comparing the different regions among the patients with  $\Delta DA \geq 0.1 \text{ mm}^2$ , there was no significant  
152 difference between  $FD_{ED}$  and  $FD_{ND}$  ( $43.61 \pm 4.36 \%$  [median: 44.22, IQR: 46.02 – 40.93] and  $44.16 \pm 2.38\%$   
153 [median: 45.22, IQR: 45.83 – 42.52],  $p=528$ ), but these were both significantly higher than  $FD_{DF}$  ( $p=0.001$   
154 and  $p < 0.001$  respectively) (Fig. 3).

### 155 **Repeatability assessment**

156 Between graders, the ICC of all DA measurements was 0.992 (95% confidence interval (CI) 0.964-  
157 0.999) while the calculation of the FD had an ICC of 0.951 (95% CI 0.931-0.983) in the drusen free  
158 regions, 0.867 (95% CI 0.821-0.935) in the region of enlarged drusen, and 0.905 (95% CI 0.871-0.963) in  
159 the region of new drusen.

160

## 161 **Discussion**

162           In this study we retrospectively investigated the status of the choriocapillaris in different regions  
163 of the macula in eyes with early/intermediate AMD and correlated CC flow deficit in these regions with  
164 the subsequent development or enlargement of drusen. Both regions demonstrating new incident  
165 drusen or enlargement of existing drusen, showed greater CC flow deficits compared to regions which  
166 did not show involvement by drusen.

167           Several studies using different approaches have demonstrated a strong association between  
168 microvascular choroidal changes and AMD from early to advanced stages. Histopathological studies  
169 have highlighted increasing CC alterations with age and the presence of drusen[21–23] .

170 It has been suggested that the location in which drusen appear may not be stochastic, but may be  
171 influenced by the anatomy of the underlying CC.[24, 25] For example, Lengyel et al. demonstrated a  
172 spatial relationship between equatorial drusen and intercapillary pillars of the CC, which may represent  
173 an initial site of drusen deposition[26]. Furthermore an increased sub-RPE deposit density has been  
174 correlated with CC loss and the development of drusen over areas of the choroid with ghost vessels [27].  
175 However, this topic is still debated as other authors reported RPE atrophy with a preserved  
176 choriocapillaris at the edges of GA [28, 29]. Bhutto and Lutty, following a comprehensive literature  
177 review, postulated that RPE dysfunction may represent the trigger for atrophic AMD, whereas in  
178 exudative AMD, a primary insult to the choroidal vasculature might lead to the subsequent disruption of  
179 the RPE/ Bruch's membrane/choroidal vascular complex [30].

180           The mechanism(s) driving the RPE alterations (i.e. drusen, pigment changes, and eventual  
181 atrophy) and the basis for the predilection of these alterations to form in regions associated with CC



182 impairment, is still unknown. One hypothesis is that primary CC vascular impairment, due to  
183 inflammatory or degenerative mechanisms or other genetic and non-genetic factors, may lead to RPE  
184 ischemia and dysfunction[31–33]. Alternatively, as the CC relies on vascular endothelial growth factor  
185 (VEGF) secretion by the RPE, early dysfunction of the overlying RPE cells could impair this trophic  
186 signaling process leading to endothelial cell loss[29, 34].

187 Several OCTA studies have now investigated CC alterations at nearly all stages of AMD[11, 13, 15, 35–  
188 39].

189 Our group recently studied the CC features in eyes affected by intermediate AMD, confirming the co-  
190 localization of the CC flow impairment under and around the edges of drusen [15, 38].

191 To the best of our knowledge, this study is the first to report two important findings: (1) there is a  
192 significant impairment of the choriocapillaris in the area of future drusen enlargement; given that, we  
193 may hypothesize that CC impairment may be a key factor influencing enlargement of the drusenoid  
194 lesions; (2) there is a significant flow impairment in areas with intact RPE where a new drusen lesion will  
195 develop within 2 years of follow-up (Fig. 4). Interestingly, there was no difference in the CC flow deficit  
196 overall between eyes which showed an increase in drusen area at follow-up, compared to those that did  
197 not show much change in area. This observation would appear to highlight the importance of  
198 regional/loval changes in the CC compared to more diffuse changes in these early and intermediate  
199 AMD eyes.

200 This observation is perhaps not surprising as these regions of greater CC impairment would be expected  
201 to be associated with a greater impairment of the overlying RPE. One would expect that these more  
202 impaired RPE cells would be most susceptible to lipofuscin accumulation, drusen development, and  
203 eventual progressive manifest RPE alterations

204 Although the precise role of alterations of the CC in the pathogenesis of drusen and AMD requires  
205 further investigation, the results of our study may facilitate further investigations of a topographic  
206 characterization of the CC in AMD patients which may allow, in a longitudinal setting, the prediction not  
207 only of the location of the new lesions, but also their expansion.

208 Despite this mounting evidence, it is still impossible to exclude that RPE dysfunction, not revealed by  
209 current imaging modalities, may still be the primary trigger for CC flow impairment. The use of new  
210 multimodal imaging techniques including fluorescence lifetime imaging ophthalmoscopy [40, 41] or  
211 quantitative fundus autofluorescence [42–44] or adaptive optics imaging[45, 46] may eventually provide  
212 further clarity to this issue. Regardless, the status of the CC on OCTA may prove to be useful as an early  
213 biomarker of the status of the overlying RPE.

214 Among our cohort, no patients showed a reduction of drusen area during our follow-up period. A sharp  
215 reduction in drusen volume has been reported prior to the development of advanced AMD. If the  
216 patients included in our study were followed for a longer period of time, we suspect we would have  
217 observed advanced AMD events and a reduction in drusen volume in some eyes. Future studies with  
218 longer follow-up may be able to determine whether the severity of CC impairment can predict which  
219 drusen go on to develop atrophy.

220 Our study is not without limitations, including its retrospective design (with potential for selection bias)  
221 and a relatively small sample size. In addition, as this was an exclusively OCT-based study, we were not  
222 able correlate these CC findings on OCTA with abnormalities on other imaging modalities such as color  
223 photographs or FAF images. Another limitation of our study is the use of an SD-OCT system for OCT  
224 angiography. Current commercially available SD-OCT machines, use a shorter wavelength (i.e. ~840 nm)  
225 and have more sensitivity loss with depth compared with swept source systems<sup>22,23</sup>, and thus may have  
226 more difficulty achieving adequate signal levels at the CC because of its location beneath the highly

227 scattering RPE. This issue could be especially problematic under drusen. However, this was not a major  
228 concern in our study as we focused on the baseline OCTA in regions free of drusen or RPE abnormalities  
229 at baseline. Thus, our analysis is less susceptible to signal loss and related artifacts.

230 In summary, we report a significant CC flow impairment under areas of intact RPE where “old”  
231 drusen tend to expand and new incident drusen develop within 2 years of follow-up. Several structural  
232 OCT findings are already recognized as risk factors for AMD progression including drusen volume[47],  
233 intraretinal hyper-reflective foci[48, 49], hyporeflective foci within drusenoid lesions[50] and subretinal  
234 drusenoid deposits[51]. If replicated in future prospective, longitudinal studies, a more precise  
235 topographic representation of CC flow deficits on OCTA, may prove to be another useful parameter for  
236 evaluating the prognosis of these eyes.

237

## 238 **Compliance with Ethical Standards:**

239 Funding: No funding was received for this research.

240 Conflict of Interest: M. Nassisi: none; T. Tepelus: none; MG Nittala: none; S.R. Sadda: Allergan (C,F), Carl  
241 Zeiss Meditec (F), Genentech (C, F), Amgen (C), Novartis (C), Optos (C,F), Centervue (C), Heidelberg (C) ,  
242 Regeneron (F), Oxurion (C).

243 Ethical approval: Data collection was approved by the institutional review board (IRB) of the University  
244 of California – Los Angeles (UCLA). The study was performed in accordance with the Health Insurance  
245 Portability and Accountability Act and adhered the principles of the 1964 Declaration of Helsinki and its  
246 later amendments.

247

## 248 **References**

- 249 1. Bird AC, Bressler NM, Bressler SB, et al (1995) An international classification and grading system  
250 for age-related maculopathy and age-related macular degeneration. The International ARM  
251 Epidemiological Study Group. *Surv Ophthalmol* 39:367–374
- 252 2. Saksens NTM, Geerlings MJ, Bakker B, et al (2016) Rare Genetic Variants Associated With  
253 Development of Age-Related Macular Degeneration. *JAMA Ophthalmol* 134:287–293.  
254 <https://doi.org/10.1001/jamaophthalmol.2015.5592>
- 255 3. Klein R, Myers CE, Cruickshanks KJ, et al (2014) Markers of inflammation, oxidative stress, and  
256 endothelial dysfunction and the 20-year cumulative incidence of early age-related macular  
257 degeneration: the Beaver Dam Eye Study. *JAMA Ophthalmol* 132:446–455.  
258 <https://doi.org/10.1001/jamaophthalmol.2013.7671>
- 259 4. Querques G, Rosenfeld PJ, Cavallero E, et al (2014) Treatment of dry age-related macular  
260 degeneration. *Ophthalmic Res* 52:107–115. <https://doi.org/10.1159/000363187>
- 261 5. Zarbin MA, Rosenfeld PJ (2010) Pathway-based therapies for age-related macular degeneration: an  
262 integrated survey of emerging treatment alternatives. *Retina Phila Pa* 30:1350–1367.  
263 <https://doi.org/10.1097/IAE.0b013e3181f57e30>
- 264 6. Spaide RF (2016) Choriocapillaris Flow Features Follow a Power Law Distribution: Implications for  
265 Characterization and Mechanisms of Disease Progression. *Am J Ophthalmol* 170:58–67.  
266 <https://doi.org/10.1016/j.ajo.2016.07.023>
- 267 7. Al-Sheikh M, Falavarjani KG, Pfau M, et al (2017) Quantitative Features of the Choriocapillaris in  
268 Healthy Individuals Using Swept-Source Optical Coherence Tomography Angiography. *Ophthalmic*  
269 *Surg Lasers Imaging Retina* 48:623–631. <https://doi.org/10.3928/23258160-20170802-04>
- 270 8. Borrelli E, Sarraf D, Freund KB, Sadda SR (2018) OCT angiography and evaluation of the choroid and  
271 choroidal vascular disorders. *Prog Retin Eye Res*. <https://doi.org/10.1016/j.preteyeres.2018.07.002>
- 272 9. Nassisi M, Baghdasaryan E, Tepelus T, et al (2018) Topographic distribution of choriocapillaris flow  
273 deficits in healthy eyes. *PLOS ONE* 13:e0207638. <https://doi.org/10.1371/journal.pone.0207638>
- 274 10. Forte R, Haulani H, Jürgens I (2018) QUANTITATIVE AND QUALITATIVE ANALYSIS OF THE THREE  
275 CAPILLARY PLEXUSES AND CHORIOCAPILLARIS IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES  
276 MELLITUS WITHOUT CLINICAL SIGNS OF DIABETIC RETINOPATHY: A Prospective Pilot Study. *Retina*  
277 *Phila Pa*. <https://doi.org/10.1097/IAE.0000000000002376>
- 278 11. Borrelli E, Souied EH, Freund KB, et al (2018) REDUCED CHORIOCAPILLARIS FLOW IN EYES WITH  
279 TYPE 3 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION. *Retina Phila Pa*.  
280 <https://doi.org/10.1097/IAE.0000000000002198>
- 281 12. Nassisi M, Lavia C, Alovici C, et al (2017) Short-Term Choriocapillaris Changes in Patients with  
282 Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy. *Int J Mol Sci* 18:.  
283 <https://doi.org/10.3390/ijms18112468>

- 284 13. Nassisi M, Shi Y, Fan W, et al (2018) Choriocapillaris impairment around the atrophic lesions in  
285 patients with geographic atrophy: a swept-source optical coherence tomography angiography  
286 study. *Br J Ophthalmol*. <https://doi.org/10.1136/bjophthalmol-2018-312643>
- 287 14. Uji A, Balasubramanian S, Lei J, et al (2017) Impact of Multiple En Face Image Averaging on  
288 Quantitative Assessment from Optical Coherence Tomography Angiography Images.  
289 *Ophthalmology*. <https://doi.org/10.1016/j.ophtha.2017.02.006>
- 290 15. Borrelli E, Uji A, Sarraf D, Sadda SR (2017) Alterations in the Choriocapillaris in Intermediate Age-  
291 Related Macular Degeneration. *Invest Ophthalmol Vis Sci* 58:4792–4798.  
292 <https://doi.org/10.1167/iovs.17-22360>
- 293 16. Nittala MG, Ruiz-Garcia H, Sadda SR (2012) Accuracy and Reproducibility of Automated Drusen  
294 Segmentation in Eyes with Non-Neovascular Age-Related Macular Degeneration. *Invest*  
295 *Ophthalmol Vis Sci* 53:8319–8324. <https://doi.org/10.1167/iovs.12-10582>
- 296 17. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat*  
297 *Methods* 9:671–5
- 298 18. Bearely S, Chau FY, Koreishi A, et al (2009) Spectral domain optical coherence tomography  
299 imaging of geographic atrophy margins. *Ophthalmology* 116:1762–1769.  
300 <https://doi.org/10.1016/j.ophtha.2009.04.015>
- 301 19. Uji A, Balasubramanian S, Lei J, et al (2017) Choriocapillaris Imaging Using Multiple En Face Optical  
302 Coherence Tomography Angiography Image Averaging. *JAMA Ophthalmol*.  
303 <https://doi.org/10.1001/jamaophthalmol.2017.3904>
- 304 20. Spaide RF (2017) CHORIOCAPILLARIS SIGNAL VOIDS IN MATERNALLY INHERITED DIABETES AND  
305 DEAFNESS AND IN PSEUDOXANTHOMA ELASTICUM. *Retina* 1.  
306 <https://doi.org/10.1097/IAE.0000000000001497>
- 307 21. Curcio CA, Messinger JD, Sloan KR, et al (2013) Subretinal drusenoid deposits in non-neovascular  
308 age-related macular degeneration: morphology, prevalence, topography, and biogenesis model.  
309 *Retina Phila Pa* 33:265–276. <https://doi.org/10.1097/IAE.0b013e31827e25e0>
- 310 22. Mullins RF, Johnson MN, Faidley EA, et al (2011) Choriocapillaris vascular dropout related to  
311 density of drusen in human eyes with early age-related macular degeneration. *Invest Ophthalmol*  
312 *Vis Sci* 52:1606–1612. <https://doi.org/10.1167/iovs.10-6476>
- 313 23. Ramrattan RS, van der Schaft TL, Mooy CM, et al (1994) Morphometric analysis of Bruch's  
314 membrane, the choriocapillaris, and the choroid in aging. *Invest Ophthalmol Vis Sci* 35:2857–2864
- 315 24. Friedman E, Smith TR, Kuwabara T (1963) Senile choroidal vascular patterns and drusen. *Arch*  
316 *Ophthalmol Chic Ill* 1960 69:220–230
- 317 25. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP (1999) Early drusen formation in the normal and  
318 aging eye and their relation to age related maculopathy: a clinicopathological study. *Br J*  
319 *Ophthalmol* 83:358–368

- 320 26. Lengyel I, Tufail A, Hosaini HA, et al (2004) Association of drusen deposition with choroidal  
321 intercapillary pillars in the aging human eye. *Invest Ophthalmol Vis Sci* 45:2886–2892.  
322 <https://doi.org/10.1167/iovs.03-1083>
- 323 27. Mullins RF, Johnson MN, Faidley EA, et al (2011) Choriocapillaris vascular dropout related to  
324 density of drusen in human eyes with early age-related macular degeneration. *Invest Ophthalmol*  
325 *Vis Sci* 52:1606–1612. <https://doi.org/10.1167/iovs.10-6476>
- 326 28. Seddon JM, McLeod DS, Bhutto IA, et al (2016) Histopathological Insights Into Choroidal Vascular  
327 Loss in Clinically Documented Cases of Age-Related Macular Degeneration. *JAMA Ophthalmol*  
328 134:1272–1280. <https://doi.org/10.1001/jamaophthalmol.2016.3519>
- 329 29. Korte GE, Reppucci V, Henkind P (1984) RPE destruction causes choriocapillary atrophy. *Invest*  
330 *Ophthalmol Vis Sci* 25:1135–1145
- 331 30. Bhutto I, Luty G (2012) Understanding age-related macular degeneration (AMD): Relationships  
332 between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris  
333 complex. *Mol Aspects Med* 33:295–317. <https://doi.org/10.1016/j.mam.2012.04.005>
- 334 31. Biesemeier A, Taubitz T, Julien S, et al (2014) Choriocapillaris breakdown precedes retinal  
335 degeneration in age-related macular degeneration. *Neurobiol Aging* 35:2562–2573.  
336 <https://doi.org/10.1016/j.neurobiolaging.2014.05.003>
- 337 32. Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related  
338 macular degeneration. *Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp*  
339 *Ophthalmol* 242:91–101. <https://doi.org/10.1007/s00417-003-0828-0>
- 340 33. Cabrera AP, Bhaskaran A, Xu J, et al (2016) Senescence Increases Choroidal Endothelial Stiffness  
341 and Susceptibility to Complement Injury: Implications for Choriocapillaris Loss in AMD. *Invest*  
342 *Ophthalmol Vis Sci* 57:5910–5918. <https://doi.org/10.1167/iovs.16-19727>
- 343 34. McLeod DS, Grebe R, Bhutto I, et al (2009) Relationship between RPE and choriocapillaris in age-  
344 related macular degeneration. *Invest Ophthalmol Vis Sci* 50:4982–4991.  
345 <https://doi.org/10.1167/iovs.09-3639>
- 346 35. Sacconi R, Corbelli E, Carnevali A, et al (2017) OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY  
347 IN GEOGRAPHIC ATROPHY. *Retina Phila Pa*. <https://doi.org/10.1097/IAE.0000000000001873>
- 348 36. Moulton EM, Waheed NK, Novais EA, et al (2016) SWEPT-SOURCE OPTICAL COHERENCE  
349 TOMOGRAPHY ANGIOGRAPHY REVEALS CHORIOCAPILLARIS ALTERATIONS IN EYES WITH NASCENT  
350 GEOGRAPHIC ATROPHY AND DRUSEN-ASSOCIATED GEOGRAPHIC ATROPHY. *Retina Phila Pa* 36  
351 Suppl 1:S2–S11. <https://doi.org/10.1097/IAE.0000000000001287>
- 352 37. Cicinelli MV, Rabiolo A, Marchese A, et al (2017) Choroid morphometric analysis in non-  
353 neovascular age-related macular degeneration by means of optical coherence tomography  
354 angiography. *Br J Ophthalmol* 101:1193–1200. <https://doi.org/10.1136/bjophthalmol-2016-309481>  
355

- 356 38. Borrelli E, Shi Y, Uji A, et al (2018) Topographical Analysis of the Choriocapillaris in Intermediate  
357 Age-related Macular Degeneration. *Am J Ophthalmol* 196, Pages 34-43.  
358 <https://doi.org/10.1016/j.ajo.2018.08.014>
- 359 39. Arya M, Sabrosa AS, Duker JS, Waheed NK (2018) Choriocapillaris changes in dry age-related  
360 macular degeneration and geographic atrophy: a review. *Eye Vis* 5:  
361 <https://doi.org/10.1186/s40662-018-0118-x>
- 362 40. Sauer L, Klemm M, Peters S, et al (2017) Monitoring foveal sparing in geographic atrophy with  
363 fluorescence lifetime imaging ophthalmoscopy - a novel approach. *Acta Ophthalmol (Copenh)*.  
364 <https://doi.org/10.1111/aos.13587>
- 365 41. Dysli C, Wolf S, Berezin MY, et al (2017) Fluorescence lifetime imaging ophthalmoscopy. *Prog Retin*  
366 *Eye Res* 60:120–143. <https://doi.org/10.1016/j.preteyeres.2017.06.005>
- 367 42. Burke TR, Duncker T, Woods RL, et al (2014) Quantitative fundus autofluorescence in recessive  
368 Stargardt disease. *Invest Ophthalmol Vis Sci* 55:2841–2852. <https://doi.org/10.1167/iovs.13-13624>
- 369 43. Armenti ST, Greenberg JP, Smith RT (2016) Quantitative Fundus Autofluorescence for the  
370 Evaluation of Retinal Diseases. *J Vis Exp JoVE*. <https://doi.org/10.3791/53577>
- 371 44. Eandi CM, Nassisi M, Lavia C, et al (2017) Macular Pigment Density and Quantitative Fundus  
372 Autofluorescence in Young Healthy Subjects. *Invest Ophthalmol Vis Sci* 58:2284–2290.  
373 <https://doi.org/10.1167/iovs.16-20510>
- 374 45. Querques G, Kamami-Levy C, Georges A, et al (2014) Appearance of regressing Drusen on adaptive  
375 optics in age-related macular degeneration. *Ophthalmology* 121:611–612.  
376 <https://doi.org/10.1016/j.ophtha.2013.10.006>
- 377 46. Gocho K, Sarda V, Falah S, et al (2013) Adaptive optics imaging of geographic atrophy. *Invest*  
378 *Ophthalmol Vis Sci* 54:3673–3680. <https://doi.org/10.1167/iovs.12-10672>
- 379 47. Abdelfattah NS, Zhang H, Boyer DS, et al (2016) Drusen Volume as a Predictor of Disease  
380 Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. *Invest*  
381 *Ophthalmol Vis Sci* 57:1839–1846. <https://doi.org/10.1167/iovs.15-18572>
- 382 48. Nassisi M, Fan W, Shi Y, et al (2018) Quantity of Intraretinal Hyperreflective Foci in Patients With  
383 Intermediate Age-Related Macular Degeneration Correlates With 1-Year Progression. *Invest*  
384 *Ophthalmol Vis Sci* 59:3431–3439. <https://doi.org/10.1167/iovs.18-24143>
- 385 49. Lei J, Balasubramanian S, Abdelfattah NS, et al (2017) Proposal of a simple optical coherence  
386 tomography-based scoring system for progression of age-related macular degeneration. *Graefes*  
387 *Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol* 255:1551–1558.  
388 <https://doi.org/10.1007/s00417-017-3693-y>
- 389 50. Ouyang Y, Heussen FM, Hariri A, et al (2013) Optical coherence tomography-based observation of  
390 the natural history of drusenoid lesion in eyes with dry age-related macular degeneration.  
391 *Ophthalmology* 120:2656–2665. <https://doi.org/10.1016/j.ophtha.2013.05.029>

392 51. Spaide RF, Ooto S, Curcio CA (2018) Subretinal drusenoid deposits AKA pseudodrusen. Surv  
393 Ophthalmol 63:782–815. <https://doi.org/10.1016/j.survophthal.2018.05.005>

394

395

396

397

398

399

400

401

402

## 403 **Figure Legends**

404 **Figure 1.** *The 6x6 mm drusen maps generated from the baseline and follow-up visits (A and C) were*  
405 *registered with the OCT angiogram (B) and automatically cut, obtaining two 3x3 mm maps (D and F).*  
406 *The latter were binarized to obtain the drusen areas (G and I) while the choriocapillaris (CC) angiogram*  
407 *was binarized to analyze the percentage of flow deficits (E). In figure H the drusen area from the baseline*  
408 *visit is highlighted with a white line, while the area from the follow-up visit is highlighted with a yellow*  
409 *line (H). In figure H, the region outside the white line is the drusen free region, while “#” represents the*  
410 *region of enlarged drusen and “\*” the regions of new drusen.*

411 **Figure 2.** *Flow chart diagram explaining the selection process of eligible eyes for the study. Among the*  
412 *initial cohort of 95 subjects with early or intermediate age related macular degeneration (AMD) in at*



413 least one eye, only 48 met all the inclusion criteria and were included in the analysis. OCT-A: Optical  
414 coherence tomography angiography; SSI: Signal Strength Index;  $\Delta DA$ : difference in drusen area between  
415 the baseline and the follow-up visit.

416 **Figure 3.** Box plots showing the percentage of flow deficits in the patients where the difference between  
417 the follow-up and baseline drusen area ( $\Delta DA$ ) was inferior or superior to  $0.1 \text{ mm}^2$ . Flow deficits were  
418 calculated in the drusen free region (DF) in the region of enlarged drusen (ED) and in the region of new  
419 incident drusen (ND). Significant *p* values are shown in red. All *p* values were calculated with a Mann-  
420 Whitney U test.

421 **Figure 4.** Two patients (rows) with an eye with intermediate age-related macular degeneration .  
422 Registered 3x3mm drusen maps for the baseline (A and E) and follow-up visit (B and F) were used to  
423 delineate the drusen areas. After binarization of the optical coherence tomography angiography  
424 choriocapillaris slab (C and G) the percentages of flow deficits were calculated in the regions between the  
425 baseline area (white line) and follow-up area (yellow line) (D and H). The percentage of flow deficits (FD)  
426 in the first patient was 36.86 % and 44.93 % in the drusen free region ( $FD_{DF}$ ) and in the region of enlarged  
427 drusen ( $FD_{ED}$ ) respectively. The second patient had a  $FD_{DF}$  of 42.23% while  $FD_{ED}$  and FD in the region of  
428 new drusen were 44.53 % and 45.13%.

429

430